Fig. 2: Efficacy of alternating osimertinib and gefitinib in participants with EGFR-T790M positive advanced NSCLC. Source data are provided as source data file. | Nature Communications

Fig. 2: Efficacy of alternating osimertinib and gefitinib in participants with EGFR-T790M positive advanced NSCLC. Source data are provided as source data file.

From: A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE

Fig. 2

a Kaplan-Meier estimate of progression-free survival (PFS) for evaluable participants (n = 47). b Kaplan-Meier estimate of overall survival (OS) for evaluable participants (n = 47). c Waterfall plot with best percentage tumor change from baseline target lesions and best confirmed overall response for evaluable participants (n = 47). d Spider plot demonstrating response to treatment for each participant over time (n = 47). e Swimmer plot showing duration on treatment for 47 evaluable participants. Individual participants represented as lines. Line segments are colored according to treatment, with blue representing gefitinib and grey representing osimertinib, and dark grey representing dose interruptions. A red dot indicates progressive disease, and a black dot indicates death. f Kaplan-Meier estimate of PFS for evaluable participants (n = 46) stratified according to activating epidermal growth factor receptor (EGFR) mutation (EGFRm) type. Ex19del, exon 19 deletion, 95% CI, 95% confidence interval.

Back to article page